WO2005089447A2 - Streptococcus agalactiae vaccine - Google Patents
Streptococcus agalactiae vaccine Download PDFInfo
- Publication number
- WO2005089447A2 WO2005089447A2 PCT/US2005/008972 US2005008972W WO2005089447A2 WO 2005089447 A2 WO2005089447 A2 WO 2005089447A2 US 2005008972 W US2005008972 W US 2005008972W WO 2005089447 A2 WO2005089447 A2 WO 2005089447A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- streptococcus agalactiae
- fish
- composition
- agalactiae
- vaccine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
Definitions
- Streptococcus agalactiae is a Group B streptococcal bacterium that causes severe economic losses in a number of species of cultured and wild fish. This infectious bacterium is common in aquaculture facilities where fish are intensively cultured in fresh, brackish, or marine waters. The high densities of fish and the aqueous environment favor the rapid transmission of streptococcal disease. Moreover, infected cultured fish may transmit the disease to wild fish populations, or infected wild fish may transmit the disease to cultured fish.
- the toxoid-enriched bacterin vaccine was a combination of two formalin-killed Enterococcus sp. isolates and their culture fluids.
- Rainbow trout ⁇ Oncorhynchus mykiss) immunized with formalin-killed Streptococcus sp. in Freund's incomplete adjuvant were protected against Streptococcus sp., whereas trout immunized by bath immersion were not protected [Akhlaghi et al., Comparison of passive and active immunization of fish against streptococcosis (enterococcosis), J Fish Dis 1996; 19: 251- 258]. Recently, Nakanishi et al.
- Streptococcus difficile is a nonhemolytic group B, type lb Streptococcus, Int J Syst Bacteriol, 1997; 47(1): 81-85
- S. difficile reported by Eldar et al. was actually a non-hemolytic, group B Streptococcus, S. agalactiae.
- group B Streptococcus S. agalactiae
- streptococcal fish isolates originally unspeciated or misidentified have been more recently characterized as nonhemolytic, group B Streptococcus, S. agalactiae.
- the vaccines comprise intact (whole) killed cells of one or more /3-hemolytic isolates of Streptococcus agalactiae, and the concentrated extract from a culture of a /3-hemolytic Streptococcus agalactiae.
- the vaccine composition is effective for the protection of fish against infection by the same or other virulent strains Streptococcus agalactiae ⁇ i.e., different from the isolate(s) of S. agalactiae used to prepare the vaccine).
- Another object of this invention is to provide a vaccine which is effective in preventing epizootics in fish populations caused by S. agalactiae.
- Yet another object of this invention is to provide an effective vaccine against S. agalactiae which may be administered by injection or bath immersion.
- Yet another object of this invention is to provide both monovalent and polyvalent vaccines against S.
- An additional object of this invention is to provide novel isolates of /3-hemolytic S. agalactiae from fish which may be used for the preparation of vaccines against S. agalactiae infection in fish.
- a still further object of this invention is to improve the viability and productivity of tilapia, striped bass and other fish species, and to reduce economic losses thereto caused by S. agalactiae.
- Other objects and advantages of the invention will become readily apparent from the ensuing description. Brief Description of the Figures Figure 1 shows the mean percent cumulative mortality of tilapia administered S. iniae vaccine by intrapentoneal (IP) injection and IP challenged with 2.6 x 10 4 CFU S.
- FIG. 1 shows the mean percent cumulative mortality of tilapia administered S. agalactiae vaccine (trials 3 and 4) by intraperitoneal (IP) injection and IP challenged with S. agalactiae. T; Trial 3 challenge dose 2.6 x 10 3 CFU/fish ( ⁇ vaccinates; V non-vaccinates); Trial 4 challenge dose 1.5 x 10 4 CFU/fish (_ vaccinates; _ non-vaccinates).
- Figure 3 shows the daily mortality of tilapia administered S. agalactiae vaccine (trials 5 and 6) by bath immersion and IP challenge with S. agalactiae.
- Figure 4 shows the relationship between mean glucose values (mg/dL) (lines) and percent cumulative mortality (bars) in challenged tilapia at different time points post- challenge. Percent cumulative mortality in the 10 vaccinated (striped bar) and control (black bars) tilapia and mean blood glucose levels in the vaccinated (striped line) and control (black line) tilapia challenged with 1.5 x 10 4 CFU of S. agalactiae by IP injection. Deposit of Biological Material Beta hemolytic, encapsulated S.
- agalactiae brain isolates (ARS-KU-3 B and ARS- KU-11 B) were deposited on July 17, 2002, under the provisions of the Budapest Treaty in the Agricultural Research Service Culture Collection located at 1815 North University Street, Peoria, IL 61604, and have been assigned Deposit Accession No.'s NRRL B-30608 and NRRL B-30607, respectively.
- Streptococcus agalactiae refers to the recognized species, the characteristics of which are described by Evans et al.
- vaccine is defined in its broad sense to refer to any type of biological agent in an administratable form capable of stimulating a protective immune response in an animal inoculated with the vaccine.
- the present invention provides novel vaccines comprising one or more killed, ⁇ - hemolytic isolates of S. agalactiae in the form of intact (whole) cells, in combination with a concentrated extract from a culture of the same or different isolate of /3-hemolytic S. agalactiae.
- the vaccines are effective for controlling infection of fish by any strain of S. agalactiae, including strains which are different from those used in the preparation of the vaccine.
- the vaccines are effective for controlling infections by /3-hemolytic and non-hemolytic strains, as well as encapsulated or non-encapsulated strains.
- the vaccine is particularly effective for eliciting a protective response in fish against infection by /3-hemolytic strains of S. agalactiae.
- the vaccines of this invention are effective in controlling infection by S. agalactiae in a variety of fish when administered thereto. Vaccination also significantly reduces abnormal behavior and morphology in the treated fish.
- the vaccine is especially beneficial for the treatment of domestic or exotic fish, including golden shiners, bullminnows, bluefish, gulf menhaden, sea catfish, mullet, pinfish, Atlantic croaker, spot, weakfish, channel catfish, rainbow trout, eels, striped bass and their hybrids, sea bass, sea bream, turbot, and tilapia.
- the particular strain of /3-hemolytic S. agalactiae used for preparation of the vaccines is not critical, and any beta-hemolytic, encapsulated or non-encapsulated, isolate of Streptococcus agalactiae is suitable for use herein. Suitable S.
- agalactiae may be isolated from environmental or natural sources such as infected fish using conventional and enrichment techniques similar to those described by Evans et al. (Characterization of /3-haemolytic Group B Streptococcus agalactiae in cultured seabream, Sparus auratus L., and wild mullet, Liza klunzingeri (Day), in Kuwait, Journal of Fish Diseases 2002; 25:505- 513, the contents of which are incorporated by reference herein), or from previously isolated substantially pure strains.
- Preferred strains include those which are encapsulated, particularly the above-mentioned strains NRRL B-30608 and NRRL B-30607.
- the inventive vaccine is a killed cell preparation or bacterin, which also includes a concentrated fraction of the extracellular filtrate (cell-free culture fluid) of a culture of S. agalactiae.
- the concentrated fraction is substantially free of cells, cell wall fragments, and intracellular components of S. agalactiae.
- the skilled practitioner will recognize that a relatively small amount of intracellular products and cell wall fragments may be present as the result of normal cell lysis occurring during the course of culture.
- low molecular weight extracellular components are removed from the concentrated fraction, preferably those having a molecular weight less than about 1 kDa, more preferably those having a molecular weight less than about 2kDa, and most preferably those having a molecular weight less than about 3 kDa.
- various low molecular weight components of the extracellular products of killed S. agalactiae have an inhibitory effect upon the antigenicity of the bacterin suspensions. Concentration and filtration of the extracellular retentate substantially removes these inhibitory components and thus increases efficacy of the vaccine.
- the extracellular products are believed to include antigens from the capsule or secreted/excreted antigens and other beneficial molecules providing a superior immunization response.
- Propagation of the bacterium for preparation of the vaccine may be effected by culture under any conventional conditions and on media which promote its growth. Although a variety of conventional solid and liquid media may be suitable for use herein, growth in liquid culture is particularly preferred for large scale production. Without being limited thereto, conventional tryptic soy broth is preferred, although additional nutrients may be added to enhance capsule (polysaccharide) production. For example, the addition of sugar such as glucose may enhance polysaccharide production.
- the production of the vaccine may be conducted by stationary culture of the selected isolate without adjusting the culture pH during the fermentation at 25°C for 5 to 7 days.
- Starving S. agalactiae cells by a prolonged fermentation time of 5 to 7 days, is also believed to enhance the efficacy of the resultant vaccine, and thus is preferred.
- the final pH value of the vaccine prepared in this medium may range from pH 6.5 to 7.4.
- the salinity of the vaccine preparation is preferably in the range of 3.6-4.0 parts per thousand (ppt) salt (YSI Incorporated, Yellow Springs, OH) and it is believed that this property may also enhance the effectiveness of the vaccine, especially when administered by the bath immunization method.
- the vaccine (produced as described in Example 2) measured by a clinical refractometer (Atago A300CL, Vee Gee Scientific, Inc., Kirkland, WA) is 1.3384 to 1.3387 on the serum protein (g/100ml) scale; is 1.015 to 1.016 on the urine specific gravity (UG) scale and refractive index (nD) at 589 nanometers (nm) is 1.0 to 1.2.
- the optical density (OD) of the vaccine at 540 nm UV-Visible Spectrophotometers, Spectronic Unicam, Cambridge, UK) is in the range of 0.887 to 0.939. Aeration is generally not preferred.
- All vegetable based fermentation media are also preferred for use herein, as the use thereof eliminates the risks of the presence of animal products and infectious agents in the final vaccine product.
- cells of S. agalactiae are subjected to chemical and/or physical treatment effective to kill ⁇ i.e., inactivate) the cells.
- An effective treatment for killing the cells is defined herein as that which kills 99.9% or more of the viable cells, without lysing the cells and while retaining the ability of the cells to elicit an antibody response in the animal.
- the treatment should not substantially alter the specificity of the cell surface antigens on the killed cells relative to the untreated cells.
- killed, intact S. agalactiae are prepared by treatment of the viable cells with formalin.
- the cells may be killed by UV irradiation such as described by Purdy et al. (U.S. Patent No. 6,303,130) for the preparation of Pasteurella haemolytica bacterins.
- bacterins are also suitable for use herein, and include but are not limited to treatment with alcohols, particularly an aliphatic alcohol such as ethanol or isopropyl alcohol, phenol, tricresol, formalin, formaldehyde, acetone, merthiolate, /3-lactones, and moderate heat at temperatures which would not induce protein denaturation ⁇ e.g., 56°C for 1 hour). Treatment times and conditions will of course vary with the particular method selected and may be readily determined by routine testing. In the preferred embodiment, the S.
- alcohols particularly an aliphatic alcohol such as ethanol or isopropyl alcohol, phenol, tricresol, formalin, formaldehyde, acetone, merthiolate, /3-lactones, and moderate heat at temperatures which would not induce protein denaturation ⁇ e.g., 56°C for 1 hour.
- Treatment times and conditions will of course vary with the particular method selected and may be readily determined by routine testing. In the preferred embodiment, the S.
- agalactiae cells in their fermentation container are exposed to formalin for a sufficient period of time to kill 100% of the cells.
- formalin concentration would range from about 1 % to about 5% (v/v), preferably from about 1 % to about 3% (v/v).
- Suitable exposure times for a particular formalin concentration to achieve 100% killing may be readily determined from lethal killing curves of % killed vs. time of treatment.
- the cells are concentrated, for example, by filtration or centrifugation to obtain a high density suspension of cells, and the cell pellet and fermentation culture fluid are separated. The separated cells may be retained for use as the first component of the vaccine.
- the filtrate in the form of the cell-free culture fluid, is then itself subjected to another concentration step to produce the concentrated extract, and preferably to remove the above-mentioned low-molecular weight extracellular components.
- a variety of filtration systems, with different molecular weight cut-offs, are suitable for use in this preferred embodiment.
- Preferred filters include those having a molecular weight cutoff of approximately 1 kDa, producing a concentrated extract comprising extracellular products from the culture having a molecular weight greater than about 1 kDa.
- the cell-free culture fluid is concentrated by use of a 3 kDa Amicon column (S3Y3) using a Millipore Proflux M12 (Billerica, MA).
- separation may be carried out to completion, with water added to re-suspend the retentate. In a particularly preferred embodiment, separation may be carried out until there has been a five-fold reduction in retentate volume.
- the killed cells and concentrated extract will typically be prepared from the same culture. However, it is recognized that they may be prepared from different cultures of the same or different strains of S. agalactiae. Appropriate ratios may be determined by those skilled in the art, but are seen to typically range from about 5:1 (vol/vol) to about 20:1 (vol/vol), preferably about 10:1 (vol/vol) of the original fermentation cell-free culture fluid [i.e., the ratio of the original volume of the cell-free culture fluid to the concentrated culture fluid (retentate) volume].
- the concentrated cell-free culture fluid is sterilized using a 0.22 Fm 1 I microbiological filter (Coming, Corning, NY). Sixteen ml of the formalin-killed cells are added to 1000 ml of the sterilized concentrated cell-free fermentation fluid. Following re-suspension of the cell pellet in the retentate, the killed S. agalactiae cells are prepared for administration by formulation in an immunologically effective amount or dosage to the fish. The dose may either be given as simply the retentate containing the re-suspended killed cells, or may further include pharmaceutically acceptable carriers and adjuvants known in the art.
- An immunologically effective amount or dosage is defined herein as being that amount which will induce complete or partial immunity (elicit a protective immune response) in a treated fish against subsequent challenge with virulent strain of S. agalactiae. Immunity is considered as having been induced in a population of treated animals when the level of protection for the population (evidenced by a decrease in the number of infected fish or a decrease in the severity of infection) is significantly higher than that of an unvaccinated control group (measured at a confidence level of at least 80%, preferably measured at a confidence level of 95%).
- the appropriate effective dosage can be readily determined by the practitioner skilled in the art by routine experimentation.
- the vaccine will contain at least 1 x 10 8 cells of S.
- agalactiae/ ⁇ of bath medium preferably about 4 x 10 9 cells of S. agalactiae/m ⁇ of bath medium.
- a preferred dose in a fish would be about 0.1 - 0.2 ml of the amount above.
- greater amounts of cells may be administered, use of such higher levels is generally considered impractical.
- the killed cells are prepared for administration by formulation in a pharmaceutically acceptable carrier such as water, physiological saline, mineral oil, vegetable oils, aqueous sodium carboxymethyl cellulose, or aqueous polyvinylpyrrolidone.
- the vaccine formulations may also contain optional adjuvants, antibacterial agents or other pharmaceutically active agents as are conventional in the art.
- suitable adjuvants include but are not limited to mineral oil, vegetable oils, alum, and Freund's incomplete adjuvant.
- Still other preferred adjuvants include microparticles or beads of biocompatible matrix materials.
- the microparticles may be composed of any biocompatible matrix materials as are conventional in the art, including but not limited to, agar and polyacrylate.
- carriers or adjuvants may be used as well.
- adjuvants which may be used are described by Webb and Winkelstein [in Basic & Clinical Immunology, Stites et al. (ed.), fifth edition, Lange Medical Publications, Los Altos, CA, 1984, pages 282-285], the contents of which are incorporated by reference herein.
- the killed cells may be incorporated into microparticles or microcapsules to prolong the exposure of the antigenic material to the subject animal and hence increase the duration of protective immunity.
- the microparticles and capsules may be formed from a variety of well-known inert, biocompatible matrix materials using techniques conventional in the art.
- suitable matrix materials include natural or synthetic polymers such as alginates, poly(lactic acid), poly(lactic/glycolic acid), poly(caprolactone), polycarbonates, polyamides, polyanhydrides, polyortho esters, polyacetals, polycyanoacrylates, polyurethanes, ethytlene-vinyl acetate copolymers, polystyrenes, polyvinyl chloride, polyvinyl fluoride, poly(vinyl imidazole), chlorosulphonated polyolefins, polyethylene oxide, and particularly agar and polyacrylates.
- natural or synthetic polymers such as alginates, poly(lactic acid), poly(lactic/glycolic acid), poly(caprolactone), polycarbonates, polyamides, polyanhydrides, polyortho esters, polyacetals, polycyanoacrylates, polyurethanes, ethytlene-vinyl acetate copolymers, polystyrenes, polyvinyl chloride
- the vaccines of the invention may be administered to the subject animal by any convenient route which enables the cells to elicit an immune response, such as by intraperitoneal or intramuscular injection, bath immersion, oral administration, or nasal administration.
- intraperitoneal injection or bath immersion is preferred for primary immunization
- oral immunization is preferred for secondary or booster immunization, when necessary.
- the surface of the fish may be punctured such as described by Nakanishi et al. (2002, ibid) or otherwise abraded or slightly descaled, prior to or during bath immersion, to facilitate exposure of the vaccine to the animal's immune system.
- the vaccine may be administered in a single dose or in a plurality of doses.
- the vaccine may be administered in multiple doses, the timing of which may be readily determined by the skilled artisan.
- Vaccination against infection by S. agalactiae by bath immersion immunization ffers several advantages over other routes of immunization. Among these advantages are lower cost per fish immunized, mass immunization of large numbers of fish, reduced stress, significantly higher rates of fish survival and the absence of adverse reactions to vaccination.
- bath immersion vaccination is an effective method for mass vaccination of smaller fish that can not be injected or subjected to skin punctures.
- intraperitoneal injection of commercially available fish vaccines is commonly employed on fresh or marine aquaculture farms due to their reliability and high efficacy despite high cost per fish immunized and stress to the fish.
- EXAMPLE 1 The S. iniae vaccine developed previously by Klesius et al. was evaluated for efficacy against S. agalactiae. The vaccine was not protective.
- tilapia were from stocks maintained at the ARS, USDA, Aquatic Animal Health Research Laboratory (Auburn, AL). Tilapia with mean weights of five and 30 g were acclimated in flow-through 57 1 glass aquaria supplied with 0.5 l/h de-chlorinated water for 10 days prior to experiments. A light and dark period of 12 h: 12 h was maintained and aeration was supplied by an air stone. The fish were fed daily to satiation with AQUAMAX GROWER 400 (Brentwood, MO). Water quality was monitored, with dissolved oxygen, temperature and salinity measured daily using a YSI 85 oxygen conductivity, salinity, and temperature meter (Yellow Spring Instrument Co., Yellow Springs, OH).
- iniae vaccine was previously described (Klesius et al., Efficacy of a killed Streptococcus iniae vaccine in tilapia ⁇ Oreochromis niloticus), Bull Eur Ass Fish Pathol, 1999; 19(1 ): 38-41.1999). Briefly, vaccines were prepared by separate culture of Streptococcus iniae isolates (NRRL B-30264 and NRRL B-30238) in tryptic soy broth (TSB) and incubated in a shaker (70 RPM) water bath at 27°C for 72 hours. Cultures were treated with 10% neutral buffered formalin to give a final concentration of 3% at 27°C for 24 hours.
- TTB tryptic soy broth
- the formalin treated cultures were centrifuged at 7000 x g for 30 minutes and cell pellet and culture fluid separated.
- the cell free culture fluid was concentrated 20 fold using a 2 kDa hollow fiber concentrator to remove all components of lower molecular weight. This 2 kDa culture fluid concentrate was then used to re-suspend the cell pellet at V/V of 10:1.
- the final concentration of the vaccine was 4 x 10 9 CFU/ml.
- the bacterial concentration was estimated by taking the optical density of the vaccine prior to killing by formalin. The actual number of CFU/ml was determined using a spiral autoplater and Qcount (Spiral Biotech, Norwood, MA). Non-vaccinates received concentrated tryptic soy broth (TSB) only.
- the vaccine cells were determined to be killed by lack of growth on sheep blood agar at 72 hours.
- Vaccination protocol To determine whether the S. iniae vaccine was protective against S. agalactiae (trial 1 ), two hundred tilapia with mean weight of 30 g were divided into 10 tanks of 20 fish each, including non-immunized controls (Table 1 ). Five replicate tanks of tilapia served as controls.
- the S. iniae NRRL B-30264 or the combined NRRL B-30264/NRRL B-30238 vaccines were intraperitoneally injected in a volume of 0.1 ml into tilapia. Control tilapia received 0.1 ml of TSB.
- agalactiae isolated from mullet ⁇ Liza klunzingeri designated ARS-KU-11 B (National Agricultural Research Collection NRRL B-30607)
- ARS-KU-11 B National Agricultural Research Collection NRRL B-30607
- TTB tryptic soy broth
- the infectious isolate used in this study was prepared by inoculating TSB with a thawed aliquot of the frozen isolate. Fish were then challenged with 2.6 x 10 5 CFU/ml by IP injection with 100 ⁇ l S. agalactiae.
- Dead fish were removed twice a day and at postmortem examination, specimens were obtained aseptically from brain, anterior kidney and intestines. Specimens were cultured directly onto sheep blood agar at 27°C for 24 to 48 h. Beta-hemolytic, catalase-negative and Gram-stained positive coccus colonies were sub-cultured onto sheep blood agar and then bacteriologically and biochemically identified as S.
- TLB tryptic soy broth
- EXAMPLE 2 The S. agalactiae vaccines of this invention were evaluated for efficacy against S. agalactiae. In contrast to the S. iniae vaccines of Example 1 , the S. agalactiae vaccines were protective.
- Tilapia The tilapia were from stocks maintained at the ARS, USDA, Aquatic Animal Health Research Laboratory (Auburn, AL). Tilapia with mean weights of five and 30 g were acclimated in flow-through 57 I glass aquaria supplied with 0.5 l/h de-chlorinated water for 10 days prior to experiments. A light and dark period of 12 h: 12 h was maintained and aeration was supplied by an air stone. The fish were fed daily to satiation with AQUAMAX GROWER 400 (Brentwood, MO).
- Vaccine preparation Vaccines were prepared by separate culture of S. agalactiae isolates (NRRL B- 30608 and NRRL B-30607) in tryptic soy broth (TSB) and incubated in a shaker (70 RPM) water bath at 27°C for 72 - 125 h. Cultures were treated with a final 3% neutral buffered formalin concentration for 24 h. The formalin treated culture was centrifuged at 7,000 x g for 30 minutes and cell pellet and culture fluid separated. The cell-free culture fluid was concentrated five-fold on a 3 kDa Amicon column (S3Y3) using a Millipore Proflux M12 (Billerica, MA).
- the concentrated cell-free culture fluid was sterilized using a 0.22 Fm 1 I microbiological filter (Corning, Corning, NY). Sixteen ml of the formalin-killed cells were added to 1 I of the sterilized concentrated cell-free culture fluid.
- the vaccine had an optical density of 1.9 at 540 nm.
- the number of colony forming units (CFU)/ml of S. agalactiae in the final vaccine preparation was estimated to be 4 x 10 9 .
- the bacterial concentration was estimated by taking the optical density of the vaccine prior to killing by formalin. The actual number of CFU/ml was determined using a spiral autoplater and Qcount (Spiral Biotech, Norwood, MA).
- Non-vaccinates received concentrated tryptic soy broth (TSB) only.
- the vaccine cells were determined to be killed by lack of growth on sheep blood agar at 72 hours.
- Vaccination protocol Intraperitoneal administration Three IP S. agalactiae vaccine trials (trials 2-4) were conducted. For trial 2, forty 5 g tilapia were divided into two groups of 20 fish each. For trial 3, two hundred 30 g tilapia were divided into 10 tanks of 20 fish each. Five replicate tanks of tilapia served as controls. For trial 4, one hundred and sixty 30 g tilapia were divided into six groups (3 replicate tanks of non-immunized controls and vaccinates) of 26-27 fish per group. Trials 2 and 4 were conducted at 32°C and trial 3 was conducted at 26°C. For all trials, the vaccine was IP injected at a volume of 0.1 ml into tilapia.
- Control tilapia were IP injected with sterile TSB at the same volume. Bath immersion administration Two S. agalactiae vaccine immersion trials (trials 5-6) were performed at 32°C. For trial 5, one hundred and thirty 5 g tilapia were divided into two groups of 65 (control) and 65 (immunized) fish. Control tilapia were immersed in 1 I of 500 ml sterile water: 500 ml TSB for 20 min and, following immersion, 20-25 fish were placed in three replicate aquaria. Immunized fish were immersed in undiluted vaccine containing 16 ml bacterin and 1000 ml toxoid for 20 min with air and, following immersion, 2-25 fish were placed in three replicate aquaria.
- Control fish were immersed in TSB using the same procedure.
- Experimental challenge and bacteriologic sample evaluation At 30-64 days post-vaccination, the groups of vaccinates and non-vaccinates were weighed and IP challenged with 0.1 ml of a homologous (ARS-KU-MU-11 B) or heterologous (ARS-KU-MU-3B) S. agalactiae isolate at cell concentrations ranging from 2.6 ⁇ 10 3 to 1.7 x 10 6 CFU /fish (Table 2) and monitored daily for clinical signs and mortality for 14 days. Infected tilapia were observed for behavioral and pathological signs of erratic swimming.
- ARS-KU-MU-11 B homologous
- ARS-KU-MU-3B heterologous
- Dead fish were removed twice a day and bacterial samples were obtained aseptically from the brain, anterior kidney, and intestine of 20 % of morbid and dead fish to confirm the presence of S. agalactiae.
- Samples were cultured onto sheep blood agar (Remel, Lenexa, KS). Beta-hemolytic, oxidase-negative, and Gram-stained positive coccus colonies were identified as S. agalactiae using RAPID ID 32 STREP TEST (bioMerieux Vitek, Hazelwood, MO). The mean percent mortality and mean percent cumulative mortality of vaccinated and non-vaccinated tilapia for each trial was determined over a 14 d period.
- the efficacy of the vaccine was calculated as relative percent survival (RPS) (Amend, 1981). Statistics Significant differences in mortality between immunized and non-immunized controls after challenge for each trial were statistically analyzed by T-test and Lifetest according to procedures of the SAS Institute, Cary, NC (1997). Significant differences were determined at P ⁇ 0.05. (See previous). Results Vaccine efficacy The mean percent mortality and RPS of S. agalactiae vaccinated and non- vaccinated tilapia following S. agalactiae challenge are shown in Table 2. In contrast to S. iniae IP vaccination and challenge with S. agalactiae, 30 g tilapia IP vaccinated with S.
- FIG. 1 shows the daily mean percent cumulative mortality for S. agalactiae vaccinated and non-vaccinated fish after challenge with S. agalactiae.
- the mean percent cumulative mortality in the S. agalactiae vaccinates remained at 15-16 % from day 3 to 14. Highly significant differences in mortality between immunized and non- immunized controls were seen in trials 3 and 4.
- Example 3 The S. agalactiae vaccines of this invention were again examined for efficacy in preventing infection by virulent S. agalactiae, and the effect on blood glucose levels was also determined.
- Infected tilapia were observed for behavioral and pathological signs of erratic swimming.
- Dead fish were removed twice a day and bacterial samples were obtained aseptically from the brain, anterior kidney, and intestine and cultured onto SBA to confirm the presence of S. agalactiae.
- Beta-hemolytic, oxidase-negative, and Gram positive coccus colonies were identified as S. agalactiae using RAPID ID 32 STREP TEST (bioMerieux Vitek, Hazelwood, MO) (Evans et al., 2002).
- the cumulative treatment mortality was determined over a 13 d period.
- the efficacy of the vaccine was calculated as relative percent survival (RPS) (Amend, 1981 ).
- Blood glucose levels of the vaccinates remained elevated at 6 h post-injection but not statistically elevated before returning to pre-injection levels at 24 h. No significant differences were noted in blood glucose between vaccinates and controls prior to vaccination (Oh) or at 6 and 24 h after vaccination. Blood glucose levels of controls IP injected with TSB were not significantly different at any time interval. No mortality was noted in controls or vaccinates 28 d post-vaccination. After challenge and infection with 1.5 x 104 CFU of S. agalactiae by IP injection, both vaccinates and controls had significantly higher blood glucose levels at 2, 24, 48, and 72 h than at pre-challenge 0 h ( Figure 4).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007504124A JP2007532485A (en) | 2004-03-18 | 2005-03-18 | Group B Streptococcus vaccine |
CA002559969A CA2559969A1 (en) | 2004-03-18 | 2005-03-18 | Streptococcus agalactiae vaccine |
EP05730111A EP1732597A4 (en) | 2004-03-18 | 2005-03-18 | Streptococcus agalactiae vaccine |
IL178078A IL178078A0 (en) | 2004-03-18 | 2006-09-14 | Streptococcus agalactiae vaccine for fish |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/807,575 US7204993B2 (en) | 2004-03-18 | 2004-03-18 | Streptococcus agalactiae vaccine |
US10/807,575 | 2004-03-18 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2005089447A2 true WO2005089447A2 (en) | 2005-09-29 |
WO2005089447A3 WO2005089447A3 (en) | 2007-04-12 |
Family
ID=34986574
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2005/008972 WO2005089447A2 (en) | 2004-03-18 | 2005-03-18 | Streptococcus agalactiae vaccine |
Country Status (9)
Country | Link |
---|---|
US (1) | US7204993B2 (en) |
EP (1) | EP1732597A4 (en) |
JP (1) | JP2007532485A (en) |
CN (1) | CN101068566A (en) |
CA (1) | CA2559969A1 (en) |
CR (1) | CR8638A (en) |
EC (1) | ECSP066916A (en) |
IL (1) | IL178078A0 (en) |
WO (1) | WO2005089447A2 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7204993B2 (en) * | 2004-03-18 | 2007-04-17 | The United States Of America As Represented By The Secretary Of Agriculture | Streptococcus agalactiae vaccine |
JP2007326794A (en) * | 2006-06-06 | 2007-12-20 | Kyoritsu Seiyaku Kk | Inactivated vaccine using fish streptococcus dysgalactiae as antigen |
CN104906568A (en) * | 2015-04-09 | 2015-09-16 | 广西壮族自治区水产科学研究院 | Tilapia mossambica streptococcus agalactiae oral attenuated freeze-dried vaccine |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008003734A1 (en) * | 2006-07-06 | 2008-01-10 | Intervet International B.V. | Combination vaccine against streptococcus |
EP2403353B1 (en) * | 2009-03-06 | 2019-08-14 | Kenneth William Gregg | Composition for controlling fish |
WO2011044576A2 (en) * | 2009-10-09 | 2011-04-14 | Children's Medical Center Corporation | Selectively disrupted whole-cell vaccine |
BR112012009309B1 (en) | 2009-10-19 | 2021-10-05 | Intervet International B.V | COMBINED VACCINE, USE OF MICRO-ORGANISMS CELLS, METHOD FOR THE PREPARATION OF A COMBINED VACCINE, AND, KIT OF PARTS |
CN101890159B (en) * | 2010-06-23 | 2012-07-25 | 广西壮族自治区水产研究所 | Method for preparing bivalent inactivated vaccine of tilapia streptococcus |
JP5962892B2 (en) * | 2011-02-18 | 2016-08-03 | 共立製薬株式会社 | Sea surface aquaculture fish vaccine preparation and infectious disease prevention method |
CN102847146B (en) * | 2011-09-15 | 2013-12-11 | 通威股份有限公司 | Vaccine used for preventing tilapia streptococcal disease |
CN102676683B (en) * | 2012-05-31 | 2014-02-26 | 广西壮族自治区水产研究所 | Method for screening candidate bacterial strain from fish streptococcus agalactiae vaccine |
CN106029091B (en) | 2014-02-12 | 2020-02-11 | 特郎萨格以色列有限公司 | Algal-based edible vaccines |
IL230970A0 (en) * | 2014-02-13 | 2014-09-30 | Univ Ramot | Tilapia lake virus vaccines |
CN104152368B (en) * | 2014-03-11 | 2016-09-28 | 广西壮族自治区水产科学研究院 | Rofe source of fish streptococcus agalactiae low virulent strain and application |
CN105334324B (en) * | 2015-11-06 | 2017-06-27 | 通威股份有限公司 | Streptococcusagalactiae monoclonal antibody and its production and use |
CN112386683A (en) * | 2020-11-06 | 2021-02-23 | 中国水产科学研究院淡水渔业研究中心 | Bivalent inactivated vaccine of tilapia-derived streptococcus agalactiae extracellular product and preparation method thereof |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4207414A (en) * | 1978-08-16 | 1980-06-10 | President And Fellows Of Harvard College | Polysaccharide antigens |
US4324887A (en) * | 1978-08-16 | 1982-04-13 | President And Fellows Of Harvard College | Type II group B Streptococci polysaccharide |
US4425330A (en) * | 1981-05-20 | 1984-01-10 | Cornell Research Foundation, Inc. | Bovine mastitis vaccine and method for detecting efficacy thereof |
US5780448A (en) * | 1995-11-07 | 1998-07-14 | Ottawa Civic Hospital Loeb Research | DNA-based vaccination of fish |
JP2001161355A (en) * | 1999-11-25 | 2001-06-19 | Natl Sci Council | Immortal cell line obtained from epinephelus coioides of family serranidae and application thereof |
US6379677B1 (en) * | 2000-02-25 | 2002-04-30 | The United States Of America As Represented By The Secretary Of The Department Of Agriculture | Streptococcus iniae vaccine |
US20030125292A1 (en) * | 2001-11-07 | 2003-07-03 | Sean Semple | Mucoscal vaccine and methods for using the same |
US7204993B2 (en) * | 2004-03-18 | 2007-04-17 | The United States Of America As Represented By The Secretary Of Agriculture | Streptococcus agalactiae vaccine |
-
2004
- 2004-03-18 US US10/807,575 patent/US7204993B2/en not_active Expired - Fee Related
-
2005
- 2005-03-18 CN CNA200580013779XA patent/CN101068566A/en active Pending
- 2005-03-18 EP EP05730111A patent/EP1732597A4/en not_active Withdrawn
- 2005-03-18 JP JP2007504124A patent/JP2007532485A/en active Pending
- 2005-03-18 WO PCT/US2005/008972 patent/WO2005089447A2/en active Application Filing
- 2005-03-18 CA CA002559969A patent/CA2559969A1/en not_active Abandoned
-
2006
- 2006-09-14 IL IL178078A patent/IL178078A0/en unknown
- 2006-09-18 CR CR8638A patent/CR8638A/en not_active Application Discontinuation
- 2006-10-10 EC EC2006006916A patent/ECSP066916A/en unknown
Non-Patent Citations (1)
Title |
---|
See references of EP1732597A4 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7204993B2 (en) * | 2004-03-18 | 2007-04-17 | The United States Of America As Represented By The Secretary Of Agriculture | Streptococcus agalactiae vaccine |
JP2007326794A (en) * | 2006-06-06 | 2007-12-20 | Kyoritsu Seiyaku Kk | Inactivated vaccine using fish streptococcus dysgalactiae as antigen |
CN104906568A (en) * | 2015-04-09 | 2015-09-16 | 广西壮族自治区水产科学研究院 | Tilapia mossambica streptococcus agalactiae oral attenuated freeze-dried vaccine |
Also Published As
Publication number | Publication date |
---|---|
WO2005089447A3 (en) | 2007-04-12 |
ECSP066916A (en) | 2007-01-26 |
JP2007532485A (en) | 2007-11-15 |
CR8638A (en) | 2007-05-30 |
IL178078A0 (en) | 2008-03-20 |
US7204993B2 (en) | 2007-04-17 |
EP1732597A2 (en) | 2006-12-20 |
CA2559969A1 (en) | 2005-09-29 |
US20050208077A1 (en) | 2005-09-22 |
CN101068566A (en) | 2007-11-07 |
EP1732597A4 (en) | 2008-02-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005089447A2 (en) | Streptococcus agalactiae vaccine | |
Evans et al. | Efficacy of Streptococcus agalactiae (group B) vaccine in tilapia (Oreochromis niloticus) by intraperitoneal and bath immersion administration | |
US5294441A (en) | Avirulent microbes and uses therefor: salmonella typhi | |
DK2421556T3 (en) | Vaccines comprising attenuated strains of Mycoplasma bovis and method of attenuation | |
Pasnik et al. | Duration of protective antibodies and correlation with survival in Nile tilapia Oreochromis niloticus following Streptococcus agalactiae vaccination | |
US6350454B1 (en) | Attenuated Pasteurella piscicida vaccine for fish | |
US5855880A (en) | Avirulent microbes and uses therefor | |
US5284653A (en) | Fish vaccine comprising an avirulent, invasive bacterium | |
DE69133219T2 (en) | AVIRULENT SALMONELLA MICROBES WITH A MUTATION IN THE CDT GEN AND THEIR USE | |
US6010705A (en) | Attenuated, invasive vaccines against fish pathogens | |
US6379677B1 (en) | Streptococcus iniae vaccine | |
Daly et al. | Characterization of attenuated Renibacterium salmoninarum strains and their use as live vaccines | |
McCarthy et al. | Immunization of rainbow trout, Salmo gairdneri Richardson, against bacterial kidney disease: preliminary efficacy evaluation | |
US8637049B2 (en) | Attenuated live vaccines for aquatic animals | |
EP2912198B1 (en) | Immunogenic composition against aeromonas hydrophila | |
US6019981A (en) | Modified live Edwardsiella ictaluri against enteric septicemia in channel catfish | |
US7067122B1 (en) | Modified live Edwardsiella tarda vaccine for aquatic animals | |
TW200843789A (en) | Vaccine against fish-pathogenic bacteria | |
CA1336956C (en) | Pasteurella multocida vaccine | |
Shaw et al. | Evans et a | |
Chart et al. | Antibodies to lipopolysaccharide and outer membrane proteins of Salmonella enteritidis PT4 are not involved in protection from experimental infection | |
DE69826712T2 (en) | VACCINES CONTAINING WEAKED BACTERIA | |
US6991793B2 (en) | Method of protecting fish against columnaris disease with modified live Flavobacterium columnare | |
US6153202A (en) | In ovo methods for utilizing live Edwardsiella ictaluri against enteric septicemia in channel catfish | |
NEWMAN et al. | Immunization of salmonids against furunculosis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12006501799 Country of ref document: PH Ref document number: 178078 Country of ref document: IL Ref document number: 2668/KOLNP/2006 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007504124 Country of ref document: JP Ref document number: 2559969 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2006/010654 Country of ref document: MX Ref document number: 2005730111 Country of ref document: EP Ref document number: CR2006-008638 Country of ref document: CR |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 06104440 Country of ref document: CO Ref document number: 1200601705 Country of ref document: VN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580013779.X Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWP | Wipo information: published in national office |
Ref document number: 2005730111 Country of ref document: EP |
|
ENPW | Started to enter national phase and was withdrawn or failed for other reasons |
Ref document number: PI0508856 Country of ref document: BR Kind code of ref document: A2 Free format text: PEDIDO RETIRADO POR NAO CUMPRIMENTO DA EXIGENCIA PUBLICADA NA RPI NO 2095 DE 01/03/2011. |